Source:http://linkedlifedata.com/resource/pubmed/id/19036081
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2009-1-30
|
| pubmed:abstractText |
Mantle cell lymphoma (MCL) has a dismal outcome when treated with conventional chemotherapy. This single arm phase 2 study evaluated intensive consolidation treatment of patients with newly diagnosed MCL up to the age of 65 years, responsive to R-CHOP (rituximab, cyclophosphamide, oncovin, adriamycin, prednisolone). Endpoints for evaluation were toxicity, failure-free survival (FFS) and overall survival (OS). Eighty-seven patients were treated with three cycles of R-CHOP. Sixty-six patients responded to R-CHOP with at least a partial response, 62 continued protocol treatment with high-dose cytarabine (Ara-C; 2000 mg/m(2), bid. over 4 d) and 61 patients received rituximab and stem cell harvest, followed by BEAM (carmustine, etoposide, Ara-C, melphalan) and autologous stem cell rescue. Non-haematological toxicity, grades III and IV, was seen in 8% of the patients after R-CHOP, in 22% after high-dose Ara-C and in 55% after BEAM. The overall response rate was 70% (complete response rate 64%, partial response rate 6%), FFS and OS at 4 years were 36 +/- 7% and 66 +/- 6%, respectively. The FFS and OS at 4 years from the evaluation after BEAM in the 61 R-CHOP responsive patients was 46 +/- 9% and 79 +/- 7%, respectively. In conclusion, high-dose Ara-C and BEAM with stem cell rescue in newly diagnosed MCL patients responsive to R-CHOP is a manageable treatment with respect to toxicity. This regimen leads to long-term, but probably not durable, remissions.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1365-2141
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
144
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
524-30
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:19036081-Adult,
pubmed-meshheading:19036081-Aged,
pubmed-meshheading:19036081-Antibodies, Monoclonal,
pubmed-meshheading:19036081-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19036081-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19036081-Cyclophosphamide,
pubmed-meshheading:19036081-Cytarabine,
pubmed-meshheading:19036081-Doxorubicin,
pubmed-meshheading:19036081-Drug Administration Schedule,
pubmed-meshheading:19036081-Female,
pubmed-meshheading:19036081-Follow-Up Studies,
pubmed-meshheading:19036081-Humans,
pubmed-meshheading:19036081-Lymphoma, Mantle-Cell,
pubmed-meshheading:19036081-Male,
pubmed-meshheading:19036081-Middle Aged,
pubmed-meshheading:19036081-Prednisone,
pubmed-meshheading:19036081-Prognosis,
pubmed-meshheading:19036081-Survival Analysis,
pubmed-meshheading:19036081-Treatment Outcome,
pubmed-meshheading:19036081-Vincristine
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
|
| pubmed:affiliation |
Department of Haematology, Erasmus Medical Centre, Rotterdam, The Netherlands. m.vantveer@erasmusmc.nl
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|